Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 61 publications
Treatment patterns in relapsed/refractory marginal zone lymphoma: real-world evidence from seven countries.
Journal: Future oncology (London, England)
Published: July 31, 2026
An Evaluation of Ibrutinib and Ixazomib in Patients With Relapsed/Refractory Mantle Cell Lymphoma: PrE0404.
Journal: Clinical lymphoma, myeloma & leukemia
Published: March 09, 2026
SOHO State of the Art Updates and Next Questions | Sequencing Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: January 06, 2026
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.
Journal: Blood cancer journal
Published: December 12, 2025
Brentuximab vedotin and dose attenuated chemoimmunotherapy for patients 75 years and older with diffuse large B-cell lymphoma with analysis of outcomes by frailty.
Journal: Journal of geriatric oncology
Published: October 31, 2025
Maintenance Rituximab Following Rituximab Induction for Follicular Lymphoma: A Single-Center Experience.
Journal: Clinical lymphoma, myeloma & leukemia
Published: September 02, 2025
Synthetic lethality of MCL-1 inhibition and CAR-T therapy in aggressive B-cell lymphoma.
Journal: Leukemia
Published: August 18, 2025
Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma.
Journal: Future oncology (London, England)
Published: June 19, 2025
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 08, 2025
Last Updated: 09/26/2026